Screener
Summit Therapeutics SMMT Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value: 1,000,000,000 shares authorized; 776,017,474 and 775,371,200 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 7,760 | 7,754 |
| Additional paid-in capital | 3,024,387 | 2,947,805 |
| Accumulated other comprehensive loss | (2,632) | (2,540) |
| Accumulated deficit | (2,483,583) | (2,294,159) |
| Total stockholders' equity | 545,932 | 658,860 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's common stock?
- Summit Therapeutics (SMMT) reported common stock of 1B in Q1 2026.
- How has Summit Therapeutics's common stock changed year-over-year?
- Summit Therapeutics's common stock decreased by 0.0% year-over-year, from 1B to 1B.
- What is the long-term trend for Summit Therapeutics's common stock?
- Over 5 years (2020 to 2025), Summit Therapeutics's common stock has grown at a 313.6% compound annual growth rate (CAGR), from 826K to 1B.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Summit Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude